Total knee arthroplasty (TKA), also known as a knee replacement, is a procedure performed to
reduce severe pain and improve function of the joint. Managing postoperative pain can be
challenging following TKA, and inadequate relief can lead to impaired mobility and persistent
opioid use. Adductor canal nerve blocks (ACB), have shown significant benefit in improving
postoperative analgesia and patient satisfaction. However, the local anesthetic used
currently for these blocks only provides temporary relief that wears off within 24 hours.
Liposomal bupivacaine is an extended-release local anesthetic agent that can provide up to 72
hours of pain relief, however it is unclear if its use is also effective in ACBs for knee
surgery. The purpose of this study is to determine if liposomal bupivacaine is better than
conventional bupivacaine in improving pain control, opioid consumption, and length of stay in
patients scheduled for TKA.